OpenBiome is a nonprofit stool bank based in Cambridge, MA, focused on expanding safe access to fecal microbiota transplantation (FMT) and driving research on the human microbiome. OpenBiome collects, screens, processes, and provides stool samples for FMT, a procedure used primarily to treat recurrent Clostridioides difficile (C. diff) infection and support research into microbiome-based therapeutics.
The organization operates by sourcing stool donations from healthy individuals, subjecting these donations to rigorous safety screening, and distributing processed material to hospitals and research institutions. OpenBiome's mission is two-fold: to make FMT widely and safely available for patients who need it and to catalyze scientific discovery in the field of microbiome therapeutics. By acting as a centralized, regulated source for FMT material, OpenBiome reduces barriers for clinicians and researchers, helping to standardize care and advance scientific understanding of the human microbiome.
Who Uses OpenBiome?
OpenBiome primarily serves hospitals, clinics, and research institutions across the United States and beyond that require safe, screened material for FMT procedures. Their products are used by:
- Gastroenterologists treating patients with recurrent C. diff infections
- Academic and medical researchers studying the effects of the microbiome on health and disease
- Healthcare providers seeking a reliable source of screened and processed stool for clinical use
The Technology and Standards Behind OpenBiome
OpenBiome leverages comprehensive donor screening protocols and advanced laboratory processing to ensure that every FMT preparation meets strict safety and quality standards. Their process involves detailed health screenings, pathogen testing, and controlled manufacturing environments. By providing standardized FMT preparations, OpenBiome helps ensure patient safety and consistency in both therapeutic and research applications.
Who Are OpenBiome's Competitors?
OpenBiome operates in the emerging field of microbiome therapy and stool banking. Key competitors and adjacent companies in this space include:
- Seres Therapeutics: A biotechnology company developing microbiome-based therapeutics, including defined consortia of bacterial strains for infectious and inflammatory diseases. Seres takes a drug development approach, focusing on precise microbiome interventions.
- Other regional or hospital-based stool banks: While OpenBiome is one of the largest nonprofit stool banks, some hospitals and smaller organizations maintain their own local FMT programs.
These organizations differ in their approach: OpenBiome emphasizes nonprofit access and research facilitation, while others, like Seres Therapeutics, focus on commercial drug development and proprietary microbiome therapeutics.
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like OpenBiome and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.